Suppr超能文献

炎症、免疫与阿尔茨海默病。

Inflammation, immunity, and Alzheimer's disease.

出版信息

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):129-31. doi: 10.2174/187152710791012008.

Abstract

Few topics in the field of Alzheimer's disease (AD) research have brought about the level of excitement and interest as the role of inflammation and immunity in the pathobiology and treatment of the disease. In this special issue of the journal, experts in the field give their views on how inflammatory processes and the immune system intersect- at both etiological and treatment levels- with disease biology. Collectively, nearly three decades of work are covered in this special issue, beginning with the first epidemiologic studies that showed an inverse risk relationship between AD and use of non-steroidal anti-inflammatory drugs, and ending with "immunotherapy" approaches and recent studies examining the roles of innate immune cells including microglia and peripheral mononuclear phagocytes in AD. Despite considerable work in this area, many important questions remain concerning the nature and timing of immune/inflammatory responses in the context of AD, and at what point and how to therapeutically intervene.

摘要

在阿尔茨海默病(AD)研究领域,几乎没有哪个话题能像炎症和免疫在疾病的病理生物学和治疗中的作用那样引起如此高的关注度和兴趣。在本期杂志的特刊中,该领域的专家就炎症过程和免疫系统如何在病因学和治疗水平上与疾病生物学相互作用发表了自己的看法。本期特刊涵盖了近 30 年的工作,从最初的流行病学研究开始,这些研究表明 AD 与非甾体抗炎药的使用呈负相关风险关系,一直到“免疫疗法”方法以及最近研究检查先天免疫细胞(包括小胶质细胞和外周单核吞噬细胞)在 AD 中的作用。尽管在这一领域已经开展了大量工作,但关于 AD 背景下免疫/炎症反应的性质和时间,以及在什么时间点以及如何进行治疗性干预,仍有许多重要问题悬而未决。

相似文献

1
Inflammation, immunity, and Alzheimer's disease.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):129-31. doi: 10.2174/187152710791012008.
2
Re-balancing of inflammation and abeta immunity as a therapeutic for Alzheimer's disease-view from the bedside.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):192-6. doi: 10.2174/187152710791012044.
3
The role of the immune system in Alzheimer disease: Etiology and treatment.
Ageing Res Rev. 2017 Nov;40:84-94. doi: 10.1016/j.arr.2017.08.005. Epub 2017 Sep 21.
4
Assessing activation states in microglia.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):174-91. doi: 10.2174/187152710791012053.
5
Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):132-9. doi: 10.2174/187152710791012026.
7
Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology.
CNS Neurol Disord Drug Targets. 2011 Feb;10(1):57-67. doi: 10.2174/187152711794488665.
8
Candesartan ameliorates brain inflammation associated with Alzheimer's disease.
CNS Neurosci Ther. 2018 Mar;24(3):231-242. doi: 10.1111/cns.12802. Epub 2018 Jan 24.
9
Impact of the CD40-CD40L dyad in Alzheimer's disease.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):149-55. doi: 10.2174/187152710791012099.
10
A review: inflammatory process in Alzheimer's disease, role of cytokines.
ScientificWorldJournal. 2012;2012:756357. doi: 10.1100/2012/756357. Epub 2012 Apr 1.

引用本文的文献

2
Progress of Ginsenoside Rb1 in neurological disorders.
Front Pharmacol. 2024 Jan 24;15:1280792. doi: 10.3389/fphar.2024.1280792. eCollection 2024.
4
The sex-specific interaction of the microbiome in neurodegenerative diseases.
Brain Res. 2019 Dec 1;1724:146385. doi: 10.1016/j.brainres.2019.146385. Epub 2019 Aug 13.
6
Stress injuries and autophagy in mouse hippocampus after chronic cold exposure.
Neural Regen Res. 2017 Mar;12(3):440-446. doi: 10.4103/1673-5374.202932.
8
Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches.
Front Cell Neurosci. 2014 Apr 22;8:112. doi: 10.3389/fncel.2014.00112. eCollection 2014.
9
Telomere shortening and Alzheimer's disease.
Neuromolecular Med. 2013 Mar;15(1):25-48. doi: 10.1007/s12017-012-8207-9. Epub 2012 Nov 16.

本文引用的文献

1
Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):132-9. doi: 10.2174/187152710791012026.
2
Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):140-8. doi: 10.2174/187152710791011991.
3
Impact of the CD40-CD40L dyad in Alzheimer's disease.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):149-55. doi: 10.2174/187152710791012099.
4
Microglia and inflammation in Alzheimer's disease.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):156-67. doi: 10.2174/187152710791012071.
5
Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):168-73. doi: 10.2174/187152710791011982.
6
Assessing activation states in microglia.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):174-91. doi: 10.2174/187152710791012053.
7
Re-balancing of inflammation and abeta immunity as a therapeutic for Alzheimer's disease-view from the bedside.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):192-6. doi: 10.2174/187152710791012044.
8
Amyloid-beta immunotherapy for Alzheimer's disease.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):197-206. doi: 10.2174/187152710791012017.
9
Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):207-16. doi: 10.2174/187152710791012080.
10
Alzheimer's disease: genes, proteins, and therapy.
Physiol Rev. 2001 Apr;81(2):741-66. doi: 10.1152/physrev.2001.81.2.741.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验